GlassScriptPhysician profile
Gloria A Nardella
NPI 1093101149
$6,623.04
in general payments reported to CMS, 2019-2025
23 companies · $1,740 in 2025
The $1,740 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,071 · 2022: $1,287 · 2023: $1,425 · 2024: $1,100 · 2025: $1,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,265.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,149.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $795.40 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $401.77 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $355.56 | 2022-2025 | Caplyta |
| Alkermes, INC. | $244.32 | 2022-2025 | Lybalvi, Vivitrol |
| Lilly USA, LLC | $242.41 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Indivior INC. | $211.73 | 2021-2025 | Sublocade |
| Glaxosmithkline, LLC. | $189.80 | 2023-2025 | Trelegy Ellipta |
| Ardelyx, INC. | $162.97 | 2025 | Ibsrela |
| Novo Nordisk INC | $113.04 | 2021-2023 | Ozempic, Rybelsus |
| Braeburn INC. | $96.72 | 2025 | Brixadi |
| Axsome Therapeutics, INC. | $87.58 | 2024-2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $86.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.00 | 2022-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $73.79 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $57.93 | 2025 | Purified Cortrophin Gel |
| Neurocrine Biosciences, INC. | $54.66 | 2024 | Ingrezza |
| Orexo US, INC. | $52.45 | 2024-2025 | Zubsolv |
| Biohaven Pharmaceuticals, INC. | $41.42 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.07 | 2023 | Xifaxan |
| Vanda Pharmaceuticals INC. | $37.72 | 2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $25.27 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $24.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Nardella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.